ReviewPublished 14 September 2026Animal reuse in safety assessment studies: a review of current practices, challenges and 3Rs opportunitiesJohn S. Kendrick · David A. Shaw · Marie Jourdain · Claudia Senn · Helen Beyer · Fiona R. SewellFrontiers in Toxicologydoi 10.3389/ftox.2026.1854281
Original ResearchPublished 4 September 2026Comparative in vitro safety assessments of synthetized and plant-derived cannabidiol (CBD), and pharmacokinetics of synthetized CBD: evidence of similar toxicological profiles and accumulation upon repeated oral administrationE. T. Wong · D. Bovard · W. K. Schlage · W. Xia · H. Isa · O. Sirbu · A. R. Kolli · G. N. Nikolajsen · S. S. Jensen · J. Ho · B. Phillips · J. HoengFrontiers in Toxicologydoi 10.3389/ftox.2026.1844643
ReviewPublished 30 April 2026From biosimilars to breakthroughs: regulatory convergence toward evidence-efficient development of monoclonal antibodiesSarfaraz K. NiaziFrontiers in Drug Discoverydoi 10.3389/fddsv.2026.1778468
Original ResearchPublished 30 April 2026Phα1β cardiovascular safety pharmacology using the telemetry system in ratsCelio José Castro Junior · Marcus Vinícius GomezFrontiers in Drug Discoverydoi 10.3389/fddsv.2026.1749055
ReviewPublished 15 April 2026Analytical similarity as the primary determinant of monoclonal antibody development: toward evidence-efficient regulatory frameworksSarfaraz K. NiaziFrontiers in Drug Deliverydoi 10.3389/fddev.2026.1801236
